Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance

Zhang,Wei; Ling,Dan; Tan,Jie; Zhang,Jieqing; Li,Li

doi:10.3892/or.2012.2148

Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance

Authors:
- Wei Zhang
- Dan Ling
- Jie Tan
- Jieqing Zhang
- Li Li
View Affiliations

Affiliations: Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: November 20, 2012 https://doi.org/10.3892/or.2012.2148
Pages: 637-645

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The urokinase plasminogen activator system, which consists of urokinase plasminogen activator (uPA), plasminogen activator inhibitor type-1 (PAI-1) and urokinase plasminogen activator receptor (uPAR), plays an important role in tumor invasion and metastasis, and it may be a potential diagnostic biomarker and therapeutic target in cancer. It has been found that the expression of uPA and PAI-1 in ovarian cancer is related to clinical pathologies, while their effects on the biological behavior of tumor cells and their clinical significance are still unknown. In this study, 100 tissue samples (60 samples from malignant tumors, 20 from benign tumors and 20 from controls) and 147 blood samples (49 samples each from patients with malignant tumors, benign tumors and control group, respectively) were analyzed. The positive expression levels of uPA and PAI-1 in the malignant tumor samples and their serum concentrations in the malignant group were all significantly higher than these levels in the benign tumors and controls. In addition, the levels in patients with poorly differentiated and stage III-IV cancers, cancers with metastases as well as residual tumors >2 cm after surgery, were all obviously increased, consistent with their concentrations in serum. The Cox model analysis showed that expression of uPA at the transcription level had significant associations with prognosis. In addition, uPA greatly enhanced the abilities of cell invasion, migration and adhesion through its overexpression in SKOV3 cells. Collectively, our results showed that uPA and PAI-1 play important roles in ovarian cancer development; therefore, their expression in tissues and their concentrations in serum would greatly assist the diagnosis and prediction of the prognosis in ovarian cancer.

View Figures

View References

1	Shaaban A and Rezvani M: Ovarian cancer: detection and radiologic staging. Clin Obstet Gynecol. 52:73–93. 2009. View Article : Google Scholar
2	Chen W, Zhang S, Zou X and Zhao P: Cancer incidence and mortality in China, 2006. Chin J Cancer Res. 23:3–9. 2011. View Article : Google Scholar
3	Colman RW, Wu Y and Liu Y: Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost. 104:875–885. 2010. View Article : Google Scholar : PubMed/NCBI
4	Gramling MW and Church FC: Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thromb Res. 125:377–381. 2010. View Article : Google Scholar
5	Lademann UA and Rømer MU: Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost. 100:1041–1046. 2008.PubMed/NCBI
6	Suelves M, Vidal B, Ruiz V, et al: The plasminogen activation system in skeletal muscle regeneration: antagonistic roles of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1). Front Biosci. 1:2978–2985. 2005. View Article : Google Scholar : PubMed/NCBI
7	Dorn J, Harbeck N, Kates R, et al: Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol. 22:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
8	Schmidt M, Gehrmann M, Hengstler J and Koelbl H: New prognostic and predictive factors in breast cancer. Minerva Ginecol. 62:599–611. 2010.PubMed/NCBI
9	Halamkova J, Kiss I, Pavlovsky Z, et al: Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients. Neoplasma. 58:377–385. 2011. View Article : Google Scholar
10	Czekay RP, Wilkins-Port CE, Higgins SP, et al: PAI-1: an integrator of cell signaling and migration. Int J Cell Biol. 5624812011.PubMed/NCBI
11	Cai Z, Li YF, Liu FY, Feng YL, Hou JH and Zhao MQ: Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer. Ai Zheng. 26:312–317. 2007.PubMed/NCBI
12	Borgfeldt C, Casslén B, Liu CL, Hansson S, Lecander I and Åstedt B: High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer. 79:588–595. 1998. View Article : Google Scholar
13	Gershtein ES and Kushlinskii NE: Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Bull Exp Biol Med. 131:67–71. 2001. View Article : Google Scholar : PubMed/NCBI
14	Wang GL, Wen ZQ, Xu WP, Wang ZY, Du XL and Wang F: Inhibition of lysophosphatidic acid receptor-2 expression by RNA interference decreases lysophosphatidic acid-induced urokinase plasminogen activator activation, cell invasion, and migration in ovarian cancer SKOV-3 cells. Croat Med J. 49:175–181. 2008. View Article : Google Scholar
15	Hapke S, Kessler H, de Prada NA, Benge A, Schmitt M, Lengyel E and Reuning U: Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 276:26340–26348. 2001. View Article : Google Scholar : PubMed/NCBI
16	Schmalfeld B, Kuhn W, Reuning L, et al: Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 55:3958–3963. 1995.PubMed/NCBI
17	Dorn J, Schmitt M and Kates R: imary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res. 13:1742–1748. 2007. View Article : Google Scholar : PubMed/NCBI
18	Chambers SK, Ivins CM and Carcangiu ML: Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer. 9:449–454. 1998. View Article : Google Scholar
19	Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54:2372–2377. 1994.PubMed/NCBI
20	Ellenrieder V and Adeler G: Gress TM1 invasion and metastasis in pancreatic cancer. Ann Oncol. 10:411–421. 1999. View Article : Google Scholar
21	Andreasen P, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 57:673–685. 2000. View Article : Google Scholar
22	Liu S, Bugge TH and Leppla SH: Targeting of tumor by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem. 276:17976–17984. 2001. View Article : Google Scholar : PubMed/NCBI
23	Huang S, New L, Pan Z, Han J and Nemerow GR: Urokinase plasminogen activator/urokinase specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p382 mitogen-activated protein kinase activity. J Biol Chem. 275:2661–2673. 2000. View Article : Google Scholar
24	Pepper MS, Sappino AP, Stöcklin R, Montesano R, Orci L and Vassalli JD: Upregulation of urokinase receptor expression on migrating endot helial cells. J Cell Biol. 122:673–684. 1993. View Article : Google Scholar : PubMed/NCBI